
The Washington Post @washingtonpost
Pharmaceutical giant Eli Lilly is slashing prices of commonly prescribed insulin drugs by 70 percent while capping related out-of-pocket costs at $35 a month, a move that should help address long-standing concerns about the high cost of diabetes care. https://t.co/qg44gRwxPb — PolitiTweet.org